Leason Ellis Announces the Addition of Two Pharmaceutical/Biotech Patent Attorneys
Elizabeth M. Barnhard, Formerly of Wyeth, and Dr. Susie S. Cheng, Formerly of Jones Day, Join the Firm
White Plains, NY, September 25, 2011 --(PR.com)-- Leason Ellis LLP is proud to announce that Elizabeth M. Barnhard and Susie S. Cheng, Ph.D., two highly experienced attorneys, have joined the firm’s Pharma/Biotech Practice Group.
Dr. Cheng joins the firm as Partner with an emphasis on advising clients on the development and protection of worldwide patent portfolios, involving technologies including biologics (e.g., vaccines, antisense, proteins, antibodies, stem cells, growth factors), pharmaceuticals, enzyme replacement therapies, molecular diagnostics, medical devices, drug screening, small molecules cosmetic products and personal health products. Her clients range from Fortune 500 and Forbes International 500 corporations to small and mid-sized companies.
With a Ph.D. in molecular genetics from Columbia University, College of Physicians & Surgeons, Dr. Cheng is a graduate of Brooklyn Law School. During law school, she was a student law clerk to the Honorable Jack B. Weinstein, U.S. District Court, Eastern District of New York. Dr. Cheng joins Leason Ellis from Jones Day, a general practice firm in New York City. She was previously an attorney at Pennie & Edmonds.
Elizabeth Barnhard joins the firm as Chair of the Pharma/Biotech Practice Group and Of Counsel with an emphasis on helping her clients develop comprehensive intellectual property portfolios that address their business needs and manage business issues and risks, and representing her clients in all phases of litigation involving patent, trademark, copyright and unfair competition. Ms. Barnhard has a broad range of experience with inventions involving pharmaceuticals, biologics, and biotherapeutics for diverse therapeutic areas, biotechnology, chemical engineering, chemicals, diagnostics, healthcare products and polymers.
A graduate of New York University and New York Law School, Ms. Barnhard joins Leason Ellis from Wyeth, a multi-billion dollar global pharmaceutical company, where she was Senior Patent Counsel. Prior to that, she was an attorney at Bryan Cave. She was also an attorney at Abelman Frayne & Schwab and Itkowitz & Harwood.
With the addition of Elizabeth Barnhard and Dr. Susie Cheng, Leason Ellis strengthens its pharmaceutical/biotechnology practice. David Leason, Managing Partner of the Firm, states, “Elizabeth and Susie are a tremendous addition to the firm. Their experience combined with the rest of our team enables us to provide comprehensive service for clients with biotechnology and pharmaceutical innovations from the start of research through product launch and marketing.”
“I am delighted to join Leason Ellis because of their demonstrated commitment to the biotechnology and pharmaceutical industries,” says Barnhard. “One example of that commitment is the firm’s support of the regional biotech/pharmaceutical/life sciences sector as a Founding Member of NY BioHud Valley.”
“I am thrilled to join Leason Ellis,” says Cheng. “They are growing and thriving in a down economy by offering high-quality services combined with the newest technologies to effectively serve their clients without big city pricing.”
About Leason Ellis
Leason Ellis prides itself in delivering value to its clients by providing intelligent and unexpected solutions to the legal challenges that they face. Clients of the firm benefit from the years of experience cultivated by professionals from established specialty intellectual property firms. While others are retrenching, we are expanding because our clients recognize the value in the high-quality, practical intellectual property legal advice that we provide in a cost-effective manner. We invite you to contact us and learn more about our experience and personalized approach to intellectual property law and management.
Contact:
Peter S. Sloane, 914.288.0022, sloane@leasonellis.com
###
Dr. Cheng joins the firm as Partner with an emphasis on advising clients on the development and protection of worldwide patent portfolios, involving technologies including biologics (e.g., vaccines, antisense, proteins, antibodies, stem cells, growth factors), pharmaceuticals, enzyme replacement therapies, molecular diagnostics, medical devices, drug screening, small molecules cosmetic products and personal health products. Her clients range from Fortune 500 and Forbes International 500 corporations to small and mid-sized companies.
With a Ph.D. in molecular genetics from Columbia University, College of Physicians & Surgeons, Dr. Cheng is a graduate of Brooklyn Law School. During law school, she was a student law clerk to the Honorable Jack B. Weinstein, U.S. District Court, Eastern District of New York. Dr. Cheng joins Leason Ellis from Jones Day, a general practice firm in New York City. She was previously an attorney at Pennie & Edmonds.
Elizabeth Barnhard joins the firm as Chair of the Pharma/Biotech Practice Group and Of Counsel with an emphasis on helping her clients develop comprehensive intellectual property portfolios that address their business needs and manage business issues and risks, and representing her clients in all phases of litigation involving patent, trademark, copyright and unfair competition. Ms. Barnhard has a broad range of experience with inventions involving pharmaceuticals, biologics, and biotherapeutics for diverse therapeutic areas, biotechnology, chemical engineering, chemicals, diagnostics, healthcare products and polymers.
A graduate of New York University and New York Law School, Ms. Barnhard joins Leason Ellis from Wyeth, a multi-billion dollar global pharmaceutical company, where she was Senior Patent Counsel. Prior to that, she was an attorney at Bryan Cave. She was also an attorney at Abelman Frayne & Schwab and Itkowitz & Harwood.
With the addition of Elizabeth Barnhard and Dr. Susie Cheng, Leason Ellis strengthens its pharmaceutical/biotechnology practice. David Leason, Managing Partner of the Firm, states, “Elizabeth and Susie are a tremendous addition to the firm. Their experience combined with the rest of our team enables us to provide comprehensive service for clients with biotechnology and pharmaceutical innovations from the start of research through product launch and marketing.”
“I am delighted to join Leason Ellis because of their demonstrated commitment to the biotechnology and pharmaceutical industries,” says Barnhard. “One example of that commitment is the firm’s support of the regional biotech/pharmaceutical/life sciences sector as a Founding Member of NY BioHud Valley.”
“I am thrilled to join Leason Ellis,” says Cheng. “They are growing and thriving in a down economy by offering high-quality services combined with the newest technologies to effectively serve their clients without big city pricing.”
About Leason Ellis
Leason Ellis prides itself in delivering value to its clients by providing intelligent and unexpected solutions to the legal challenges that they face. Clients of the firm benefit from the years of experience cultivated by professionals from established specialty intellectual property firms. While others are retrenching, we are expanding because our clients recognize the value in the high-quality, practical intellectual property legal advice that we provide in a cost-effective manner. We invite you to contact us and learn more about our experience and personalized approach to intellectual property law and management.
Contact:
Peter S. Sloane, 914.288.0022, sloane@leasonellis.com
###
Contact
Leason Ellis LLP
Peter S. Sloane
914-288-0022
www.leasonellis.com
Peter S. Sloane
914-288-0022
www.leasonellis.com
Contact
Categories